Tags: Biomarkers

announcements

Alzheimer’s Drug Discovery Foundation Partners with Shionogi and Janssen Pharmaceuticals for its Dia

The Alzheimer’s Drug Discovery Foundation (ADDF) announced a partnership with Shionogi & Co., Ltd.  and Janssen Pharmaceuticals, Inc. as part of its  Diagnostics Accelerator, an initiative that aims to fast-track the development of novel biomarkers for the early detection of Alzheimer's disease and related dementias.

announcements

$3.2 Million in New Funding Focused on Biomarkers and Moving Toward New Therapies

These recent investments reflect the ADDF's commitment to advancing tools for early detection, with an emphasis on exploring the different pathologies associated with aging.

announcements

Alzheimer’s Drug Discovery Foundation Announces the First Diagnostics Accelerator Award Recipients

The first four awards from the first request for proposals total up to approximately $3.5 million.

announcements

$7.1 Million in New Funding Illustrates the ADDF's Strong Support of a Diverse Pipeline

The ADDF announces $7.1 million in new investments, which reflect our strategy to advance drug discovery and clinical trials, including the development of biomarkers and prevention methods.

announcements

The ADDF Announces New Research Initiative to Advance Digital Tools for Detection for Alzheimer's

The ADDF's Diagnostics Accelerator is seeking to fund the development of digital tools to capture quantifiable biomarkers.

announcements

ADDF Statement on Biogen and Eisai Discontinuing Trials of Aducanumab

Pharmaceuticals company Biogen and its partner Eisai announced that they will cease clinical trials for aducanumab after it was indicated the trials were unlikely to succeed.

blog

Top 5 Advances in 2018

In 2018 we have seen increased investments in Alzheimer's biomarkers and increased interest in prevention.

blog

Leading Scientists Share Exciting Research Developments at the ADDF Fall Symposium

At the ADDF's Ninth Annual Fall Symposium, Richard S. Isaacson, Michelle M. Mielke, and Mark A. Mintun discussed Alzheimer's biomarkers and prevention.

blog

Two Decades of Research: The ADDF's 19th International Conference on Alzheimer’s Drug Discovery

Researchers shared updates on their approaches to developing Alzheimer's treatments at our annual conference.

announcements

19th International Conference on Alzheimer's Drug Discovery Highlights Multiple Approaches

The conference, organized by the Alzheimer's Drug Discovery Foundation, focused on gene therapy and alternative modalities for neurodegenerative diseases, progress in developing novel drugs, as well as the need for new biomarkers.